Review Article

Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease

Table 2

(a) Use of novel fecal markers to assess disease activity (inactive versus active) in IBD. (b) Correlation of novel fecal markers to assess severity in IBD.
(a)

RefAgePop.NInactiveActive valueComments

M2 pyruvate kinase (M2-PK)
[3]ACD31[5] 0.55 U/ml[26] 30 U/ml<0.005
UC50[13] 1.2 U/ml[37] 40 U/ml0.006
[4]PCD32[15] 16.5 U/g[17] 96.3 U/gNS
UC75[40] 1.5 U/g[35] 149 U/g0.0003

Myeloperoxidase (MPO)
[38]ACD32[15][18]<0.001Active: IOIBD
UC33[14][18]<0.001Truelove and Witts’ severity index

High-mobility group box (HMGB1)
[39]PCD19[8][11]NSActive:
UC21[8][13]NSActive:

Chitinase 3-like 1 (CHI3L1)
[46]PCD87[39] 18.4 ng/g[48] 632.7 ng/g<0.01Active:
UC94[50] 15.8 ng/g[44] 366.6 ng/g<0.01Active:

Human nucleic acid
[72]AUC543.9 copies/μg259.0 copies/μg<0.01Active: colitis activity

(b)

RefAgePop.Nr valueDisease severity

M2 pyruvate kinase (M2-PK)
[12]PCD17NANSPCDAI
[15]PCD470.82<0.05PCDAI
UC370.77<0.05Truelove and Witts’ severity index

Osteoprotegerin (OPG)
[27]PCD820.150.31PCDAI
0.160.21Modified PCDAI
0.100.22PCDAI with logged OPG
0.350.0001Modified PCDAI with logged OPG

Myeloperoxidase (MPO)
[36]AUC55NA0.02Endoscopy severity
NANSEndoscopic extent or histology score

Chitinase 3-like 1 (CHI3L1)
[46]PCD250.61<0.01SES-CD scoring system
0.49<0.01PCDAI
UC420.73<0.01Sum of the Matts’ score
0.47<0.01PUCAI

Human nucleic acid
[71]AUC310.59<0.05Clinical index of Rachmilewitz
0.76<0.01Endoscopic score

Age: A: adult; P: paediatric, values are median; Pop.: type of population; N: number of patients; NS: nonsignificant; square brackets []: number of patients, r: correlation coefficient; CD: Crohn’s disease; UC: ulcerative colitis; IOIBD: International Organization for the Study of Inflammatory Bowel Diseases score; PCDAI: paediatric Crohn’s disease activity index; PUCAI: paediatric ulcerative colitis activity index; SES-CD: simple endoscopic score for Crohn’s disease.